Loading…
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intelligence solutions, including reference-based pricing, negotiation services, surprise bill services, and Vistara; network solutions, such as primary networks, complementary networks, and network build and network management services; and payment and revenue integrity solutions comprising clinical negotiation, pre-payment integrity, post-payment integrity, and revenue integrity services. It also provides data and analytics solutions consists of PlanOptix, CompleteVue, BenInsights, risk scores, and supplemental carrier services. The company provides solutions to commercial healthcare payers, third party administrators, employers, brokers/consultants, providers, government healthcare payers and system integrators. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, property and casualty insurers, bill review companies and other companies involved in the claims adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in McLean, Virginia.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $965M | $467M | $-284M | $-12M | 170.1% | 3.7% | - |
| 2024 | $931M | $-1.0B | $-1.6B | $-11M | -1958.8% | -3.2% | - |
| 2023 | $962M | $652M | $-92M | $63M | -5.4% | -10.9% | - |
| 2022 | $1.1B | $158M | $-573M | $283M | -32.0% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 1,079.72 | 961.52 | 930.62 | 965.41 |
| Cost Of Revenue | 204.10 | 295.62 | 303.45 | 316.37 |
| Gross Profit | 875.62 | 665.90 | 627.17 | 649.05 |
| Operating Expense | 541.44 | 494.98 | 518.92 | 603.99 |
| Operating Income | 334.18 | 170.92 | 108.26 | 45.06 |
| EBITDA | 158.32 | 651.93 | -1,007.90 | 467.40 |
| EBIT | -257.34 | 226.15 | -1,444.34 | 18.94 |
| Pretax Income | -560.74 | -107.06 | -1,770.71 | -373.08 |
| Tax Provision | 12.17 | -15.36 | -124.88 | -88.80 |
| Net Income | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Net Income Common Stockholders | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Total Expenses | 745.53 | 790.60 | 822.37 | 920.36 |
| Interest Expense | 303.40 | 333.21 | 326.37 | 392.02 |
| Interest Income | 3.50 | 8.23 | 3.13 | 1.56 |
| Selling General And Administration | 132.14 | 74.97 | 86.84 | 158.56 |
| Normalized EBITDA | 753.34 | 604.94 | 547.82 | 495.07 |
| Normalized Income | -102.84 | -131.95 | -200.56 | -263.19 |
| Basic EPS | -36 | -5.69 | -101.92 | 0 |
| Diluted EPS | -36 | -5.69 | -101.92 | 0 |
| Tax Effect Of Unusual Items | -124.96 | 6.74 | -110.46 | -6.59 |
| Tax Rate For Calcs | 0.21 | 0.14 | 0.07 | 0.24 |
| Total Unusual Items | -595.02 | 46.99 | -1,555.73 | -27.68 |
| Total Unusual Items Excluding Goodwill | -595.02 | 46.99 | -1,555.73 | -27.68 |
| Net Income From Continuing Operation Net Minority Interest | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Reconciled Depreciation | 415.66 | 425.79 | 436.44 | 448.45 |
| Reconciled Cost Of Revenue | 197.73 | 289.85 | 299.09 | 313.34 |
| Net Interest Income | -299.90 | -324.98 | -323.24 | -390.46 |
| Net Income From Continuing And Discontinued Operation | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Total Operating Income As Reported | -362.73 | 161.98 | -1,389.93 | 28.77 |
| Diluted Average Shares | 15.97 | 16.13 | 16.15 | 0 |
| Basic Average Shares | 15.97 | 16.13 | 16.15 | 0 |
| Diluted NI Availto Com Stockholders | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Minority Interests | 0 | 0 | 0 | 0 |
| Net Income Including Noncontrolling Interests | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Net Income Continuous Operations | -572.91 | -91.70 | -1,645.83 | -284.28 |
| Other Income Expense | -595.02 | 46.99 | -1,555.73 | -27.68 |
| Special Income Charges | -662.36 | 45.03 | -1,556.20 | -25.01 |
| Gain On Sale Of Ppe | 0 | -0.85 | -8.60 | -9.36 |
| Other Special Charges | -34.55 | -53.94 | -5.18 | 7.61 |
| Impairment Of Capital Assets | 662.22 | 0 | 1,488.86 | 0 |
| Restructuring And Mergern Acquisition | 34.69 | 8.06 | 63.93 | 8.04 |
| Gain On Sale Of Security | 67.34 | 1.97 | 0.48 | -2.67 |
| Net Non Operating Interest Income Expense | -299.90 | -324.98 | -323.24 | -390.46 |
| Interest Expense Non Operating | 303.40 | 333.21 | 326.37 | 392.02 |
| Interest Income Non Operating | 3.50 | 8.23 | 3.13 | 1.56 |
| Depreciation Amortization Depletion Income Statement | 409.29 | 420.02 | 432.07 | 445.43 |
| Depreciation And Amortization In Income Statement | 409.29 | 420.02 | 432.07 | 445.43 |
| Amortization | 340.54 | 342.69 | 343.88 | 343.76 |
| Amortization Of Intangibles Income Statement | 340.54 | 342.69 | 343.88 | 343.76 |
| Depreciation Income Statement | 68.76 | 77.32 | 88.19 | 101.67 |
| General And Administrative Expense | 132.14 | 74.97 | 86.84 | 158.56 |
| Other Gand A | 120.41 | 62.48 | 68.28 | 132.79 |
| Salaries And Wages | 11.73 | 12.49 | 18.57 | 25.77 |
| Operating Revenue | 1,079.72 | 961.52 | 930.62 | 965.41 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| CTEVthis co. | CTEV | $391M | - | -2.19 | 170.1% | 9.33 |
| Enanta Pharmaceuticals, Inc. | ENTA | $402M | - | 3.18 | -126.5% | -6.01 |
| TruBridge, Inc. | TBRG | $386M | 88.72 | 2.10 | 2.4% | 13.37 |
| Weave Communications, Inc. | WEAV | $385M | - | 4.61 | -34.1% | -18.58 |
| Cerus Corporation | CERS | $385M | - | 5.75 | -24.1% |
| -52.90 |
| Niagen Bioscience, Inc. | NAGE | $381M | 23.80 | 4.97 | 22.7% | 21.23 |
| Puma Biotechnology, Inc. | PBYI | $381M | 12.26 | 2.89 | 23.9% | 6.57 |
| Viemed Healthcare, Inc. | VMD | $381M | 26.73 | 2.66 | 10.4% | 7.66 |
| Rocket Pharmaceuticals, Inc. | RCKT | $380M | - | 1.36 | -80.5% | -0.98 |
| Peer Median | - | 25.26 | 3.04 | -10.8% | 2.79 | |